Vigabatrin Patent Expiration
Vigabatrin was first introduced by Lundbeck Pharmaceuticals Llc
Vigabatrin Patents
Given below is the list of patents protecting Vigabatrin, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Vigafyde | US12576054 | Vigabatrin Liquid Pharmaceutical Composition | Jun 08, 2043 | Pyros Pharms |
| Vigafyde | US12290499 | Vigabatrin liquid pharmaceutical composition | Oct 17, 2042 | Pyros Pharms |
| Vigafyde | US12016857 | Stable liquid vigabatrin pharmaceutical composition for oral dosage | Aug 16, 2039 | Pyros Pharms |
Vigabatrin's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Vigabatrin:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Ketogenic Diet for Prevention of Epileptic Spasms in Infantile Onset Genetic Epilepsies | Heather Olson | NA |
RECRUITING
(Jul 1, 2026)
| PHASE1 |
| Treatment of Refractory Infantile Spasms With Fenfluramine | Children's Hospital of Orange County | NA |
RECRUITING
(Apr 1, 2026)
| PHASE2 |